Roth Mkm Begins Coverage on Replimune Group (NASDAQ:REPL)

Roth Mkm assumed coverage on shares of Replimune Group (NASDAQ:REPL) in a research report released on Tuesday morning, MarketBeat reports. The firm issued a buy rating and a $17.00 price objective on the stock.

A number of other equities analysts also recently weighed in on REPL. JPMorgan Chase & Co. cut their price target on shares of Replimune Group from $17.00 to $14.00 and set an overweight rating on the stock in a research note on Tuesday, August 13th. Wedbush reiterated an outperform rating and issued a $16.00 target price on shares of Replimune Group in a report on Thursday, June 6th. Barclays upped their price target on Replimune Group from $13.00 to $17.00 and gave the stock an overweight rating in a research note on Friday, June 7th. Finally, HC Wainwright lifted their price objective on Replimune Group from $12.00 to $17.00 and gave the company a buy rating in a research note on Friday, June 7th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of Buy and a consensus price target of $16.20.

Replimune Group Stock Performance

Replimune Group stock opened at $11.06 on Tuesday. The stock has a fifty day moving average price of $9.69 and a 200 day moving average price of $8.15. Replimune Group has a 52 week low of $4.92 and a 52 week high of $21.32. The firm has a market capitalization of $679.25 million, a P/E ratio of -3.41 and a beta of 1.25. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. Equities research analysts anticipate that Replimune Group will post -3.08 earnings per share for the current year.

Insider Activity at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the transaction, the chief financial officer now owns 101,057 shares in the company, valued at $1,028,760.26. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CFO Emily Luisa Hill sold 8,938 shares of Replimune Group stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $10.18, for a total transaction of $90,988.84. Following the sale, the chief financial officer now owns 101,057 shares in the company, valued at $1,028,760.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Konstantinos Xynos sold 15,881 shares of the business’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $7.50, for a total transaction of $119,107.50. Following the transaction, the insider now directly owns 117,131 shares in the company, valued at $878,482.50. The disclosure for this sale can be found here. 20.60% of the stock is owned by insiders.

Institutional Trading of Replimune Group

Several large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC boosted its holdings in Replimune Group by 236.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,207 shares of the company’s stock valued at $35,000 after purchasing an additional 2,958 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after purchasing an additional 4,946 shares in the last quarter. Point72 DIFC Ltd purchased a new position in shares of Replimune Group during the 2nd quarter valued at approximately $57,000. Quest Partners LLC acquired a new stake in shares of Replimune Group during the fourth quarter worth approximately $76,000. Finally, Diversified Trust Co bought a new stake in shares of Replimune Group in the first quarter worth $94,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.